| Nov 21 |
Iterum Therapeutics regains full Nasdaq compliance
|
| Nov 21 |
Iterum Therapeutics Regains Full Nasdaq Compliance
|
| Nov 15 |
Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial ...
|
| Nov 14 |
Iterum Therapeutics plc (ITRM) Q3 2024 Earnings Call Transcript
|
| Nov 14 |
Earnings Scheduled For November 14, 2024
|
| Nov 11 |
Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
|
| Oct 28 |
Iterum Therapeutics plc (ITRM) U.S. FDA Approval of ORLYNVAH Call (Transcript)
|
| Oct 28 |
FDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic Partnerships
|
| Oct 28 |
FDA approves Iterum’s ORLYNVAH NDA for uUTI treatment
|
| Oct 28 |
Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
|
